CN111329863A - Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia - Google Patents

Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia Download PDF

Info

Publication number
CN111329863A
CN111329863A CN202010149400.4A CN202010149400A CN111329863A CN 111329863 A CN111329863 A CN 111329863A CN 202010149400 A CN202010149400 A CN 202010149400A CN 111329863 A CN111329863 A CN 111329863A
Authority
CN
China
Prior art keywords
methyl
compound
pyrimidin
pyridin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202010149400.4A
Other languages
Chinese (zh)
Inventor
向飞
吴洁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202010149400.4A priority Critical patent/CN111329863A/en
Publication of CN111329863A publication Critical patent/CN111329863A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

The invention relates to an application of a composition containing heterocyclic compounds in preparing medicines for treating leukemia. In one aspect, there is provided the use of a composition comprising pyridylpyrimidine amines in the manufacture of a medicament for the treatment of leukaemia; in another aspect, the present invention provides the use of a composition comprising phenylcarbamoylthiazole compounds for the manufacture of a medicament for the treatment of leukemia; the invention also provides application of the quinoline compound in preparing medicaments for treating leukemia.

Description

Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to application of a composition containing a heterocyclic compound in preparation of a medicine for treating leukemia.
Background
The pyridylpyrimidine amine compound I with the structure shown in the specification is a clinically common therapeutic drug for Chronic Myelogenous Leukemia (CML), but the medicinal dose is high (100 mg-400 mg), which indicates that the anti-effect of the pyridylpyrimidine amine compound I needs to be further improved. For example, the results of the studies by Zhonghua et al show (theory and practice in diagnostics, 2010,9(05):469-472.), that imatinib acts on the IC of K562, K562/pc and K562/CYP3A5 cells50The values were (55.313. + -. 0.248), (57.043. + -. 0.486) and (72.910. + -. 0.776). mu.g/mL, respectively.
Figure BDA0002400419820000011
A study of Phenylcarbamoylthiazole compound II with the structure shown as follows, which is also an FDA approved CML therapeutic agent, Chua Shigella et al (China modern applied medicine, 2018,35(09):1275-1279.) shows that the IC50 of the compound II acting on K562 cells is about 244.00 mu g/mL, and the activity of the compound II is to be further improved.
Figure BDA0002400419820000012
Quinoline compound III with the structure shown in the specification is also a CML therapeutic drug approved by FDA, and the data quoted by Dachow of Zhejiang university in Ph.D.paper "research on the action and mechanism of hanfangchin A citrate as calmodulin antagonist against chronic myelocytic leukemia" refers to IC of bosutinib on K56250The concentration was 26.52. mu.g/L.
Figure BDA0002400419820000021
Disclosure of Invention
The invention aims to provide application of a composition containing pyridyl pyrimidinamine compounds and phenylcarbamoyl thiazole compounds in preparing a medicament for treating leukemia, wherein the anti-leukemia effect of the composition is obviously better than that of the compounds I, II and III.
In order to achieve the above objects, the present invention provides, in a first aspect, a use of a composition comprising a first pyridylpyrimidine amine compound and a second pyridylpyrimidine amine compound which are different from each other and selected from the group consisting of compounds 1 to 38 shown below, for the preparation of a medicament for the treatment of leukemia:
4,4' - (piperazine-1, 4-diylbis (methylene)) bis (N- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) benzamide) (Compound 1),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -3- ((4-methylpiperazin-1-yl) methyl) benzamide (compound 2),
4- (chloromethyl) -N- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) benzamide (compound 3),
6-methyl-N1- (4- (pyridin-3-yl) pyrimidin-2-yl) benzene-1, 3-diamine (compound 4),
n- (2-methyl-5-nitrophenyl) -4- (pyridin-3-yl) pyrimidin-2-amine (Compound 5),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) carboxamide (Compound 6),
n- (2-methyl-5- (methylamino) phenyl) -N- (4- (pyridin-3-yl) pyrimidin-2-yl) carboxamide (Compound 7),
n- (4-methyl-3- (N- (4- (pyridin-3-yl) pyrimidin-2-yl) acetamido) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) benzamide (compound 8),
4-methyl-N- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) benzamide (compound 9),
n- (3-methyl-4- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) benzamide (compound 10),
n- (4-methyl-3- ((4-methyl-6- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) benzamide (compound 11),
6-methyl-N1- (4-methyl-6- (pyridin-3-yl) pyrimidin-2-yl) benzene-1, 3-diamine (compound 12),
2-methyl-N1- (4-methyl-6- (pyridin-3-yl) pyrimidin-2-yl) benzene-1, 4-diamine (compound 13),
n- (2-methyl-5- (4- ((4-methylpiperazin-1-yl) methyl) benzoylamino) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) -N- (4- (pyridin-3-yl) pyrimidin-2-yl) benzamide (compound 14),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- (piperazin-1-ylmethyl) benzamide (compound 15),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((4- (4- ((4-methylpiperazin-1-yl) methyl) benzoyl) piperazin-1-yl) methyl) benzamide (compound 16),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((3-methylpiperazin-1-yl) methyl) benzamide (compound 17),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) pivaloamide (compound 18),
N-methyl-N- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) benzamide (compound 19),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) -N- (4- ((4-methylpiperazin-1-yl) methyl) benzoyl) benzamide (compound 20),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) -N- (4- (piperazin-1-ylmethyl) benzoyl) benzamide (compound 21),
1-methyl-4- (4- ((4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) carbamoyl) benzyl) piperazine 1-oxide (compound 22),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) benzamide (compound 23),
1-methyl-1, 4-bis (4- ((4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) carbamoyl) benzyl) piperazin-1-ium (compound 24).
4-methyl-N- (3- (2-methyl-1H-imidazol-1-yl) -5- (trifluoromethyl) phenyl) -3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzamide (compound 25),
n- (3- (1H-imidazol-1-yl) -5- (trifluoromethyl) phenyl) -4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzamide (compound 26),
n- (3- (2, 4-dimethyl-1H-imidazol-1-yl) -5- (trifluoromethyl) phenyl) -4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzamide (compound 27),
4-methyl-N- (3- (5-methyl-1H-imidazol-1-yl) -5- (trifluoromethyl) phenyl) -3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzamide (compound 28),
tert-butyl 4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzoate (compound 29),
n- (3- (4- (hydroxymethyl) -1H-imidazol-1-yl) -5- (trifluoromethyl) phenyl) -4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzamide (compound 30),
4-methyl-1- (3- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzoylamino) -5- (trifluoromethyl) phenyl) -1H-imidazole 3-oxide (Compound 31),
4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzamide (compound 32),
1- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) ethan-1-one (compound 33),
4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzoic acid (compound 34),
methyl 4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzoate (compound 35),
3- (2- ((2-methyl-5- ((3- (4-methyl-1H-imidazol-1-yl) -5- (trifluoromethyl) phenyl) carbamoyl) phenyl) amino) pyrimidin-4-yl) pyridine 1-oxide (Compound 36),
1- (3- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzoylamino) -5- (trifluoromethyl) phenyl) -1H-imidazole-4-carboxylic acid (compound 37),
4- (hydroxymethyl) -N- (3- (4-methyl-1H-imidazol-1-yl) -5- (trifluoromethyl) phenyl) -3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzamide (compound 38).
Preferably, the mass ratio of the first pyridylpyrimidine amine compound to the second pyridylpyrimidine amine compound according to the present invention is in the range of 0.01: 1-100: 1.
In another aspect, the present invention provides a use of a composition comprising a first phenylcarbamoyl thiazole compound and a second phenylcarbamoyl thiazole compound, which are different from each other, selected from the group consisting of compounds 39 to 71 shown below, for the preparation of a medicament for treating leukemia:
Figure BDA0002400419820000041
Figure BDA0002400419820000051
Figure BDA0002400419820000061
Figure BDA0002400419820000071
Figure BDA0002400419820000081
preferably, the mass ratio of the first phenylcarbamoyl thiazole compound to the second phenylcarbamoyl thiazole compound in the present invention is 0.01: 1-100: 1.
In another aspect, the present invention provides a use of a first quinoline compound and a second quinoline compound, which are different from each other, and are selected from compounds 72 to 82 shown below in the preparation of a medicament for treating leukemia:
Figure BDA0002400419820000082
Figure BDA0002400419820000091
Figure BDA0002400419820000101
preferably, the mass ratio of the first quinoline compound to the second quinoline compound is 0.01: 1-100: 1.
On the other hand, the medicament can be prepared into oral solid preparations; more preferably, the oral solid preparation is one selected from the group consisting of a capsule, a tablet and a granule.
In vitro test results show that the IC50 value of the composition disclosed by the invention on K562, K562/pc and K562/CYP3A5 cells is at ng/L level, and is obviously lower than that of the compounds I, II and III.
Detailed Description
The following description of the embodiments is only intended to aid in the understanding of the method of the invention and its core ideas. It should be noted that, for those skilled in the art, it is possible to make various improvements and modifications to the present invention without departing from the principle of the present invention, and those improvements and modifications also fall within the scope of the claims of the present invention. The following description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described.
Test example 1 inhibitory Effect of the composition on K562, K562/pc and K562/CYP3A5 cells
The invention adopts a method disclosed by Zhonghua et al (theory and practice in diagnostics, 2010,9(05):469-50The results are shown in tables 1 to 3.
TABLE 1 inhibition of K562 cells by compositions
Figure BDA0002400419820000111
Figure BDA0002400419820000121
Figure BDA0002400419820000131
TABLE 2 inhibitory Effect of the compositions on K562/pc cells
Figure BDA0002400419820000132
Figure BDA0002400419820000141
Figure BDA0002400419820000151
Figure BDA0002400419820000161
TABLE 3 inhibition of K562/CYP3A5 by the composition
Figure BDA0002400419820000162
Figure BDA0002400419820000171
Figure BDA0002400419820000181
EXAMPLE 1 oral solid preparation containing pyridylpyrimidine amine-based Compound and Process for producing the same
Prescription
Figure BDA0002400419820000182
Figure BDA0002400419820000191
Figure BDA0002400419820000201
Figure BDA0002400419820000211
Figure BDA0002400419820000221
Figure BDA0002400419820000231
Figure BDA0002400419820000241
Preparation method
The prescription dose of MIX (X-Y) and auxiliary materials are sieved by a 100-mesh sieve. Mixing MIX (X-Y), lactose, microcrystalline cellulose, polyvinylpolypyrrolidone and starch; taking the hydroxypropyl methylcellulose with the prescription amount, preparing a solution with the concentration of 10% based on the hydroxypropyl methylcellulose, adjusting the pH to 3.0-4.0 by using lactic acid, adding the solution into the mixed material to prepare a soft material, granulating by using a 16-mesh sieve, and drying for 3-4 h at 80 ℃. Granulating with 16 mesh sieve, adding prescription amount of silica gel micropowder and magnesium stearate, mixing, and encapsulating to obtain capsule with weight of 500 mg;
the prescription dose of MIX (X-Y) and auxiliary materials are sieved by a 100-mesh sieve. Mixing MIX (X-Y), lactose, microcrystalline cellulose, polyvinylpolypyrrolidone and starch; taking the hydroxypropyl methylcellulose with the prescription amount, preparing a solution with the concentration of 10% based on the hydroxypropyl methylcellulose, adjusting the pH to 3.0-4.0 by using lactic acid, adding the solution into the mixed material to prepare a soft material, granulating by using a 16-mesh sieve, and drying for 3-4 h at 80 ℃. Sieving with 16 mesh sieve, adding silica gel micropowder and magnesium stearate, mixing, and packaging to obtain granule with weight of 5g per bag.
The prescription dose of MIX (X-Y) and auxiliary materials are sieved by a 100-mesh sieve. Mixing MIX (X-Y), lactose, microcrystalline cellulose, polyvinylpolypyrrolidone and starch; taking the hydroxypropyl methylcellulose with the prescription amount, preparing a solution with the concentration of 10% based on the hydroxypropyl methylcellulose, adjusting the pH to 3.0-4.0 by using lactic acid, adding the solution into the mixed material to prepare a soft material, granulating by using a 16-mesh sieve, and drying for 3-4 h at 80 ℃. Sieving with 16 mesh sieve, adding prescription amount of silica gel micropowder and magnesium stearate, mixing, and tabletting to obtain tablet with weight of about 500 mg.

Claims (7)

1. Use of a composition comprising a first pyridylpyrimidine amine compound and a second pyridylpyrimidine amine compound which are different from each other and selected from the group consisting of compounds 1 to 38 shown below in the preparation of a medicament for the treatment of leukemia:
4,4' - (piperazine-1, 4-diylbis (methylene)) bis (N- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) benzamide) (Compound 1),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -3- ((4-methylpiperazin-1-yl) methyl) benzamide (compound 2),
4- (chloromethyl) -N- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) benzamide (compound 3),
6-methyl-N1- (4- (pyridin-3-yl) pyrimidin-2-yl) benzene-1, 3-diamine (compound 4),
n- (2-methyl-5-nitrophenyl) -4- (pyridin-3-yl) pyrimidin-2-amine (Compound 5),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) carboxamide (Compound 6),
n- (2-methyl-5- (methylamino) phenyl) -N- (4- (pyridin-3-yl) pyrimidin-2-yl) carboxamide (Compound 7),
n- (4-methyl-3- (N- (4- (pyridin-3-yl) pyrimidin-2-yl) acetamido) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) benzamide (compound 8),
4-methyl-N- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) benzamide (compound 9),
n- (3-methyl-4- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) benzamide (compound 10),
n- (4-methyl-3- ((4-methyl-6- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) benzamide (compound 11),
6-methyl-N1- (4-methyl-6- (pyridin-3-yl) pyrimidin-2-yl) benzene-1, 3-diamine (compound 12),
2-methyl-N1- (4-methyl-6- (pyridin-3-yl) pyrimidin-2-yl) benzene-1, 4-diamine (compound 13),
n- (2-methyl-5- (4- ((4-methylpiperazin-1-yl) methyl) benzoylamino) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) -N- (4- (pyridin-3-yl) pyrimidin-2-yl) benzamide (compound 14),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- (piperazin-1-ylmethyl) benzamide (compound 15),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((4- (4- ((4-methylpiperazin-1-yl) methyl) benzoyl) piperazin-1-yl) methyl) benzamide (compound 16),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((3-methylpiperazin-1-yl) methyl) benzamide (compound 17),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) pivaloamide (compound 18),
N-methyl-N- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) benzamide (compound 19),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) -N- (4- ((4-methylpiperazin-1-yl) methyl) benzoyl) benzamide (compound 20),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) -N- (4- (piperazin-1-ylmethyl) benzoyl) benzamide (compound 21),
1-methyl-4- (4- ((4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) carbamoyl) benzyl) piperazine 1-oxide (compound 22),
n- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) -4- ((4-methylpiperazin-1-yl) methyl) benzamide (compound 23),
1-methyl-1, 4-bis (4- ((4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) carbamoyl) benzyl) piperazin-1-ium (Compound 24),
4-methyl-N- (3- (2-methyl-1H-imidazol-1-yl) -5- (trifluoromethyl) phenyl) -3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzamide (compound 25),
n- (3- (1H-imidazol-1-yl) -5- (trifluoromethyl) phenyl) -4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzamide (compound 26),
n- (3- (2, 4-dimethyl-1H-imidazol-1-yl) -5- (trifluoromethyl) phenyl) -4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzamide (compound 27),
4-methyl-N- (3- (5-methyl-1H-imidazol-1-yl) -5- (trifluoromethyl) phenyl) -3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzamide (compound 28),
tert-butyl 4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzoate (compound 29),
n- (3- (4- (hydroxymethyl) -1H-imidazol-1-yl) -5- (trifluoromethyl) phenyl) -4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzamide (compound 30),
4-methyl-1- (3- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzoylamino) -5- (trifluoromethyl) phenyl) -1H-imidazole 3-oxide (Compound 31),
4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzamide (compound 32),
1- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) ethan-1-one (compound 33),
4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzoic acid (compound 34),
methyl 4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzoate (compound 35),
3- (2- ((2-methyl-5- ((3- (4-methyl-1H-imidazol-1-yl) -5- (trifluoromethyl) phenyl) carbamoyl) phenyl) amino) pyrimidin-4-yl) pyridine 1-oxide (Compound 36),
1- (3- (4-methyl-3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzoylamino) -5- (trifluoromethyl) phenyl) -1H-imidazole-4-carboxylic acid (compound 37),
4- (hydroxymethyl) -N- (3- (4-methyl-1H-imidazol-1-yl) -5- (trifluoromethyl) phenyl) -3- ((4- (pyridin-3-yl) pyrimidin-2-yl) amino) benzamide (compound 38).
2. Use according to claim 1, characterized in that the mass ratio of said first pyridylpyrimidinamine compound to said second pyridylpyrimidinamine compound is in the range from 0.01: 1-100: 1.
3. Use of a composition comprising a first phenylcarbamoyl thiazole compound and a second phenylcarbamoyl thiazole compound, which are different from each other and are selected from the group consisting of compounds 39 to 71 shown below, for the preparation of a medicament for treating leukemia:
Figure FDA0002400419810000031
Figure FDA0002400419810000041
Figure FDA0002400419810000051
Figure FDA0002400419810000061
Figure FDA0002400419810000071
4. use according to claim 3, characterized in that the mass ratio of the first phenylcarbamoyl thiazole compound to the second phenylcarbamoyl thiazole compound is in the range of 0.01: 1-100: 1.
5. Use of a first and a second quinoline compound, which are different from each other and selected from the group consisting of compounds 72 to 82 shown below, for the preparation of a medicament for the treatment of leukemia:
Figure FDA0002400419810000072
Figure FDA0002400419810000081
6. the use according to claim 5, wherein the mass ratio of the first quinoline compound to the second quinoline compound is in the range of 0.01: 1-100: 1.
7. The use according to any one of claims 1 to 6, wherein the medicament is formulated as an oral solid formulation; more preferably, the oral solid preparation is one selected from the group consisting of a capsule, a tablet and a granule.
CN202010149400.4A 2020-03-04 2020-03-04 Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia Withdrawn CN111329863A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010149400.4A CN111329863A (en) 2020-03-04 2020-03-04 Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010149400.4A CN111329863A (en) 2020-03-04 2020-03-04 Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia

Publications (1)

Publication Number Publication Date
CN111329863A true CN111329863A (en) 2020-06-26

Family

ID=71174183

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010149400.4A Withdrawn CN111329863A (en) 2020-03-04 2020-03-04 Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia

Country Status (1)

Country Link
CN (1) CN111329863A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112079821A (en) * 2020-09-14 2020-12-15 中山万汉制药有限公司 Conjugate formed by orlistat and phenylaminopyrimidine compound and preparation method and application thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112079821A (en) * 2020-09-14 2020-12-15 中山万汉制药有限公司 Conjugate formed by orlistat and phenylaminopyrimidine compound and preparation method and application thereof

Similar Documents

Publication Publication Date Title
RU2469707C2 (en) Pharmaceutical compositions containing nilotinib or its salts
EP1885339B1 (en) Formulations of a src/abl inhibitor
EP2305263B1 (en) Stabilized amorphous forms of imatinib mesylate
JP3221880B2 (en) Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition with antidepressant action
EP3417861A1 (en) Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
CN102065863A (en) Therapeutic agent for spinal canal stenosis
ZA200202289B (en) Antiviral compositions.
WO2006040779A2 (en) Controlled release gastric floating matrix formulation containing imatinib
CA2551529A1 (en) Amide derivative and medicine
EP2531179A1 (en) Pharmaceutical composition comprising n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
CN111329863A (en) Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia
JP7428356B2 (en) Pharmaceutical compositions of sorafenib with high bioavailability, oral solid preparations of sorafenib, and uses thereof
EP2497464A2 (en) Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture
CN100475212C (en) Combination of a nitrogen mustard analogue and imatinib mesylate for the treatment of chronic lymphocytic leukemia
US20080234285A1 (en) Combination of Organic Compounds
CN105213331B (en) Medicinal preparation containing pazopanib hydrochloride and preparation method thereof
KR20210058277A (en) Pyrrolopyrimidine, pyrrolopyridine, and indazole derivatives as therapeutic agents
US20100184774A1 (en) Methods of treatment
EP3378479B1 (en) Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
AU2014288866B2 (en) Oral pharmaceutical compositions comprising Imatinib mesylate
JP2020510027A5 (en)
CN110559299A (en) composition containing pyridyl pyrimidinamine compound and application thereof
CN111297865A (en) Use of heterocyclic compound-containing composition for preparing medicine for treating lung cancer
JPH1067657A (en) Multiple unit type long-acting pharmaceutical preparation
CN111743902A (en) Oral solid pharmaceutical composition containing micronized form and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20200626